AMETEK, Inc. (AME) Stock Price & How to Invest
Last updated November 2026
Short answer
AMETEK (AME) is a serial-acquirer industrial that makes electronic instruments and electromechanical devices, and it is usually owned as a high-quality compounder rather than a cyclical machinery bet. Investors typically approach it through the lens of record orders tied to AI infrastructure, aerospace and medical technology, weighed against a premium multiple near 36 times trailing earnings. As of October 16, 2026 the shares closed at $248.41, up about 19 percent year to date, with Q3 results due November 3.
AME stock price
As of 2026-11-16, AMETEK, Inc. (AME) last closed at $235.75, up 23.3% over the past year. Over the past 52 weeks it has traded between $189.90 and $258.52.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or AMETEK, Inc.'s investor relations page. Walnut is informational, not investment advice.
AME key stats
At $235.75 on November 16, 2026, AMETEK, Inc. (AME) has a market cap of $54.1B, a P/E of 33.2 on trailing earnings (24.5 on forward earnings) and a dividend yield of 0.58%. It next reports earnings around February 2, 2027 (estimated).
- Market cap
- $54.1B
- P/E (trailing)
- 33.2
- P/E (forward)
- 24.5
- EPS (trailing 12 months)
- $7.09
- Price to book
- 4.6
- Dividend yield
- 0.58%
- Beta
- 0.97
- Next earnings
- around February 2, 2027 (estimated)
Market cap, P/E and yield are measured at the $235.75 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with AMETEK, Inc. (AME)?
The last two weeks for AMETEK, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- AME closed at $235.75 on November 16, 2026, down 1.0% over the past five trading days (from $238.24).
- AMETEK, Inc. next reports quarterly results around February 2, 2027 (estimated).
- On November 6, 2026, AMETEK, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 3, 2026, AMETEK, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 3, 2026, AMETEK, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 4, 2026, Citigroup raised its target to $270.00 from $263.00 (Neutral).
- On November 4, 2026, RBC Capital raised its target to $308.00 from $291.00 (Outperform).
- On November 4, 2026, Mizuho lowered its target to $275.00 from $285.00 (Outperform).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
AMETEK, Inc. (AME) latest quarter
AMETEK reported revenue of $2.2 billion for Q3 2026, up 17% from a year earlier (AMETEK, Nov 3, 2026).
Source: AMETEK Q3 2026 results, Nov 3, 2026. Full earnings breakdown
What does AMETEK, Inc. (AME) do?
AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume.
The business model is as much capital allocation as manufacturing. AMETEK has bought hundreds of businesses over decades, layering them onto a decentralized operating system and pulling margins up through its internal operational excellence program. That shows in the numbers: operating margin near 26 percent, profit margin around 20 percent, and trailing free cash flow of roughly $1.5 billion (operating cash flow near $2.0 billion) on about $7.9 billion of trailing revenue. Q2 2026 was a record quarter, with sales up about 15 percent to roughly $2.04 billion, adjusted EPS of about $2.09 against a ~$1.99 consensus, orders up about 28 percent to a record $2.3 billion and backlog near $4.11 billion. Management raised 2026 adjusted EPS guidance to roughly $8.20 to $8.30, and analysts now average about $8.38. A $5 billion purchase of Indicor's instrumentation portfolio is expected to close in the second half. The counterweight is valuation: at $248.41 per share on October 16, 2026 and a market cap near $57 billion, the stock trades near the top of its historical range, up about 18.8 percent year to date and 34.6 percent over one year.
What's driving AMETEK, Inc. (AME)?
1. Record orders tied to AI infrastructure, aerospace and defense
Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. Demand broadened across AI data center infrastructure (power quality, thermal management and interconnect content), commercial aerospace, defense and medical technology. A backlog of that size gives revenue visibility well into 2027 and is the main reason management lifted second-half organic growth expectations. Consensus for Q3 2026 calls for revenue of about $2.13 billion and EPS of about $2.11.
2. The $5 billion Indicor instrumentation acquisition
AMETEK agreed to buy Indicor's instrumentation portfolio for about $5 billion, the largest deal in its history, with closing targeted for the second half of 2026. Management has pointed to 10 to 12 percent cost synergies. The deal extends the EIG franchise and tests whether the acquisition playbook that built the company still works at a materially larger check size. Analysts' 2027 revenue estimate of about $9.9 billion, versus about $8.45 billion for 2026, reflects the expected contribution.
3. Paragon Medical and the EMG margin story
The Electromechanical Group posted roughly 15 percent organic sales growth in Q2 2026 with about 290 basis points of core margin expansion, led by Paragon Medical. Medical contract manufacturing adds a recurring, regulated revenue stream with switching costs. Continued margin recovery at Paragon is one of the clearer internal levers on group profitability.
4. Cash generation funding the next deal
Trailing free cash flow of roughly $1.5 billion against about $2.31 billion of total debt and around $495 million of cash leaves AMETEK with substantial capacity to keep acquiring, though the Indicor purchase will use much of it. The dividend is deliberately small (roughly a 0.55 percent yield at about a 19 percent payout), because retained cash is redeployed into M&A. The compounding case rests on that reinvestment continuing to earn returns above cost of capital.
What are the risks to AMETEK, Inc. (AME)?
Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. The Indicor deal carries integration and leverage risk at a size AMETEK has not attempted before, and cost synergies of 10 to 12 percent are a target rather than a result. Roughly half of sales come from outside the United States, exposing results to currency, tariffs and global capital spending cycles, while short-cycle instrument orders can turn quickly if industrial demand cools. AI infrastructure and defense are currently strong contributors and would become concentration risks if either budget cycle reversed. Expectations into the November 3, 2026 report are elevated after four consecutive EPS beats and target increases from Morgan Stanley (to $275) and Citigroup (to $263) in October. Separately, AMETEK carries long-running environmental and toxic tort litigation related to groundwater contamination from a former subsidiary site in El Cajon, California, an ordinary-course legal exposure disclosed in its filings; no active securities-fraud class action was identified against the company as of August 2026.
What is the AMETEK, Inc. (AME) forecast?
18 analysts publish price targets on AME, averaging $287.44 as of November 2026, or +21.9% against the $235.75 share price on November 16, 2026. The published targets run from $217.00 to $325.00, a moderate spread, and the ratings split 14 buy, 6 hold, 0 sell. Over the last six months there have been 11 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full AME forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is AME a buy or a sell?
We give no verdict on AMETEK, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Record orders tied to AI infrastructure, aerospace and defense. Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. The most optimistic published target, $325.00, assumes this works close to its best case.
The case against. Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. The most pessimistic target, $217.00, is roughly what AME is worth if this bites instead.
Read the full bull and bear case on AME, including what would have to change to break either one. Walnut is not an investment adviser.
Has AMETEK, Inc. (AME) split its stock?
No. AMETEK, Inc. (AME) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is AMETEK, Inc. (AME) valued?
Market cap, P/E and dividend yield at today's price are in the AME key stats above. The business figures below come from AMETEK, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$7.86B; Q2 2026 up ~15% YoY
- Operating margin: ~26%
- Net income (TTM): ~$1.58B (~20% margin)
- Q2 2026 sales / adj. EPS: ~$2.04B (+15%) / ~$2.09 vs ~$1.99 est.
As of October 2026: As of October 16, 2026, AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 36, a forward P/E near 26 and EV/EBITDA around 23.5. The premium reflects roughly 26 percent operating margins, steady free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares closed at $248.41 against a 52-week range of roughly $183 to $261 and an average analyst target near $282, with Q3 2026 results due November 3.
Which ETFs hold AMETEK, Inc. (AME)?
If you want AME exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
Who competes with AMETEK, Inc. (AME)?
Diversified instrument and measurement compounders
Fortive, Roper Technologies, Danaher, Teledyne and Dover follow a similar playbook of buying niche, high-margin instrument businesses and running them decentrally. These are the closest structural comparables and the names AMETEK is most often valued against on multiple and capital allocation.
Test, measurement and analytical instruments
In specific EIG product lines AMETEK competes with Keysight Technologies, Bruker, MKS Instruments, Agilent, Thermo Fisher Scientific, Emerson and Honeywell across materials analysis, process instrumentation, power quality and aerospace sensing.
Electromechanical, interconnect and precision motion
EMG faces TE Connectivity and Amphenol in engineered connectors and interconnects, Parker Hannifin, Moog and Regal Rexnord in precision motion and aerospace components, and specialized contract manufacturers in the medical device supply chain where Paragon Medical operates.
What stocks are similar to AMETEK, Inc. (AME)?
Other names that sit close to AME: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in AMETEK, Inc. (AME)
There are three common ways to get AME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IWS, FMDE, JHMM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so AME sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where AME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on AMETEK, Inc. (AME)
AME is a disciplined niche-instruments compounder with record backlog and a $5 billion acquisition in flight, where the debate is whether the growth reacceleration justifies a mid-30s trailing earnings multiple. Four straight quarterly EPS beats and rising analyst targets in October 2026 frame the November 3 report.
More on AMETEK, Inc. (AME)
Whether AME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AME a buy or a sell?, and where the stock could go from here in the AME stock forecast.
For income investors, whether AME pays a dividend and how the payout looks is covered in does AME pay a dividend? And to weigh AME against a peer, read the full side-by-side comparisons: AME vs FTV and AME vs ROP.
Wondering how AME fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AMETEK, Inc.
Ask Walnut's AI anything about AME and see how it fits what you own.
FAQ
What does AMETEK actually make?
+
AMETEK makes electronic instruments and electromechanical devices. The Electronic Instruments Group builds analytical, test, process and aerospace instrumentation such as power quality monitors and materials analysis systems. The Electromechanical Group makes engineered connectors, precision motion components, thermal management products and medical device components through Paragon Medical.
Is AME a good long term compounder?
+
AMETEK is commonly grouped with Roper, Fortive and Danaher as a serial-acquirer compounder. It has bought hundreds of niche businesses over decades and lifted their margins, producing roughly 26 percent operating margins and about $1.5 billion of trailing free cash flow. Whether that record continues at larger deal sizes is the open question.
How did AMETEK do in Q2 2026?
+
It was a record quarter. Sales rose about 15 percent to roughly $2.04 billion, adjusted EPS was about $2.09 (up roughly 17 percent and ahead of the ~$1.99 estimate), orders climbed about 28 percent to a record $2.3 billion and backlog reached about $4.11 billion. Management raised full-year adjusted EPS guidance to roughly $8.20 to $8.30.
When does AMETEK report Q3 2026 earnings?
+
AMETEK reports third quarter 2026 results on November 3, 2026, followed by a webcast investor call. Analysts on average expect EPS of about $2.11 on revenue of about $2.13 billion, which would be roughly 11.5 percent EPS growth year over year. The company has beaten the EPS consensus in each of the last four quarters.
How has AME stock performed in 2026?
+
AME closed at $248.41 on October 16, 2026, up about 18.8 percent year to date and 34.6 percent over one year, and about 4.5 percent higher over the past three months. Its 52-week range runs from roughly $183 to $261, and the 18 covering analysts have an average target near $282.
Why is AME stock so expensive?
+
AMETEK trades near 36 times trailing and 26 times forward earnings as of October 2026, well above the typical industrial. The premium reflects consistently high margins, roughly 20 percent net profitability, strong cash conversion and a long acquisition track record. It also means disappointments on orders or integration can compress the multiple quickly.
What is the Indicor acquisition?
+
AMETEK agreed to acquire Indicor's instrumentation portfolio for about $5 billion, the largest deal in company history, with closing targeted for the second half of 2026. Management has guided to 10 to 12 percent cost synergies. It materially expands the Electronic Instruments Group and raises the stakes on integration execution.
Does AMETEK pay a dividend?
+
Yes, but it is small by design. The annual rate is about $1.36 per share, a yield near 0.55 percent at roughly $248, on a payout ratio around 19 percent. AMETEK deliberately retains cash to fund acquisitions rather than distribute it, so the dividend is a minor part of the total return case.
Is AMETEK an AI stock?
+
Not directly, but AI data center buildouts are now a named demand driver. AMETEK supplies power quality monitoring, thermal management and interconnect content into that infrastructure, alongside aerospace, defense and medical technology. It is a picks-and-shovels exposure rather than a pure AI play, and the diversification cuts both ways.
What are the main risks with AME?
+
The premium valuation leaves little cushion, the $5 billion Indicor deal carries integration and leverage risk at unprecedented size, and roughly half of sales come from outside the United States, adding currency and tariff exposure. Short-cycle instrument orders can also turn quickly if industrial or defense spending cools.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with AMETEK, Inc.'s investor relations page or your broker before making investment decisions.